A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

PHASE3CompletedINTERVENTIONAL

Enrollment

184

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

July 28, 2016

Study Completion Date

April 7, 2017

Conditions

Hepatitis C Virus

Interventions

DRUG

ombitasvir/paritaprevir/ritonavir

tablets

DRUG

ribavirin

tablets